Your browser doesn't support javascript.
loading
Evaluation of prognostic factors after primary chemoradiotherapy of anal cancer: A multicenter study of the German Cancer Consortium-Radiation Oncology Group (DKTK-ROG).
Martin, D; Schreckenbach, T; Ziegler, P; Filmann, N; Kalinauskaite, G; Tinhofer, I; Budach, V; Gani, C; Zips, D; Schimek-Jasch, T; Schäfer, H; Grosu, A L; Thomas, E; Krause, M; Dapper, H; Combs, S; Hoffmann, C; Stuschke, M; Walter, F; Belka, C; Kurth, I; Hadiwikarta, W W; Baumann, M; Rödel, C; Fokas, E.
Afiliação
  • Martin D; Department of Radiotherapy and Oncology, University Hospital, Goethe University, Frankfurt, Germany; Frankfurt Cancer Institute (FCI), Frankfurt, Germany; German Cancer Consortium (DKTK), Partner Site Frankfurt, and German Cancer Research Center (DKFZ), Heidelberg, Germany. Electronic address: danie
  • Schreckenbach T; Department of General and Visceral Surgery, University Hospital, Goethe University, Frankfurt, Germany.
  • Ziegler P; Frankfurt Cancer Institute (FCI), Frankfurt, Germany; German Cancer Consortium (DKTK), Partner Site Frankfurt, and German Cancer Research Center (DKFZ), Heidelberg, Germany; Senckenberg Institute of Pathology, University Hospital, Goethe University, Frankfurt, Germany.
  • Filmann N; Institute of Biostatistics and Mathematical Modeling, Goethe University, Frankfurt, Germany.
  • Kalinauskaite G; Department of Radiation Oncology, Charité-University Hospital Berlin, Germany; German Cancer Consortium (DKTK), Partner Site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Tinhofer I; Department of Radiation Oncology, Charité-University Hospital Berlin, Germany; German Cancer Consortium (DKTK), Partner Site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Budach V; Department of Radiation Oncology, Charité-University Hospital Berlin, Germany; German Cancer Consortium (DKTK), Partner Site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Gani C; Department of Radiation Oncology, Faculty of Medicine, University Hospital Tübingen, Eberhard Karls University Tübingen, Germany; German Cancer Consortium (DKTK), Partner Site Tübingen, and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Zips D; Department of Radiation Oncology, Faculty of Medicine, University Hospital Tübingen, Eberhard Karls University Tübingen, Germany; German Cancer Consortium (DKTK), Partner Site Tübingen, and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Schimek-Jasch T; Department of Radiation Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Germany; German Cancer Consortium (DKTK), Partner Site Freiburg, and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Schäfer H; Department of Radiation Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Germany; German Cancer Consortium (DKTK), Partner Site Freiburg, and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Grosu AL; Department of Radiation Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Germany; German Cancer Consortium (DKTK), Partner Site Freiburg, and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Thomas E; German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), Heidelberg, Germany; German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK) Core Center, Heidelberg, Germany; OncoRay - National Center for Radiation Research in Oncology, Faculty of Me
  • Krause M; German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), Heidelberg, Germany; German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK) Core Center, Heidelberg, Germany; OncoRay - National Center for Radiation Research in Oncology, Faculty of Me
  • Dapper H; Department of Radiation Oncology, Technical University Munich (TUM), Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich, and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Combs S; Department of Radiation Oncology, Technical University Munich (TUM), Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich, and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Hoffmann C; Department of Radiotherapy, University Hospital Essen, University of Duisburg-Essen, Germany; German Cancer Consortium (DKTK), Partner Site Essen, and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Stuschke M; Department of Radiotherapy, University Hospital Essen, University of Duisburg-Essen, Germany; German Cancer Consortium (DKTK), Partner Site Essen, and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Walter F; German Cancer Consortium (DKTK), Partner Site Munich, and German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Radiation Oncology, University Hospital LMU Munich, Munich, Germany.
  • Belka C; German Cancer Consortium (DKTK), Partner Site Munich, and German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Radiation Oncology, University Hospital LMU Munich, Munich, Germany.
  • Kurth I; German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK) Core Center, Heidelberg, Germany.
  • Hadiwikarta WW; German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK) Core Center, Heidelberg, Germany.
  • Baumann M; German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK) Core Center, Heidelberg, Germany.
  • Rödel C; Department of Radiotherapy and Oncology, University Hospital, Goethe University, Frankfurt, Germany; Frankfurt Cancer Institute (FCI), Frankfurt, Germany; German Cancer Consortium (DKTK), Partner Site Frankfurt, and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Fokas E; Department of Radiotherapy and Oncology, University Hospital, Goethe University, Frankfurt, Germany; Frankfurt Cancer Institute (FCI), Frankfurt, Germany; German Cancer Consortium (DKTK), Partner Site Frankfurt, and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Radiother Oncol ; 167: 233-238, 2022 02.
Article em En | MEDLINE | ID: mdl-34999135
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias do Ânus / Carcinoma de Células Escamosas / Quimiorradioterapia Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Radiother Oncol Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias do Ânus / Carcinoma de Células Escamosas / Quimiorradioterapia Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Radiother Oncol Ano de publicação: 2022 Tipo de documento: Article